Vugene

Vugene is a biomedical data science company that specializes in providing a multi-omics platform to enhance research productivity and innovation. Founded in 2021 in Vilnius, Lithuania, Vugene focuses on advanced biomedical data analysis and integration. The company has completed a single deal as of May 2025, and it was co-founded by individuals with a strong background in data science and biotechnology. Vugene raised EUR 1 million in venture funding led by Superhero Capital, with participation from Coinvest Capital and NGL Ventures.

Vugene specializes in biomedical data science, offering a comprehensive multi-omics platform that enhances the productivity and innovation of research processes. Their primary services include the analysis and integration of various types of biomedical data, development of analytical pipelines, and the application of machine learning and artificial intelligence techniques. The platform addresses challenges in genomics, transcriptomics, epigenomics, metabolomics, proteomics, and multi-omics integration, providing customized solutions to meet unique statistical analysis needs. Vugene serves a diverse client base including individual principal investigators, research institutions, biotech companies, bioinformaticians, hospitals, pharmaceutical companies, and contract research organizations across North America, Europe, and Asia.

Vugene generates revenue primarily through contractual partnerships and collaborations with research institutions and biotechnology firms, facilitating the delivery of their data science services. Business transactions typically involve tailored service agreements, where clients engage Vugene for specific projects related to data analysis and bioinformatics. The transaction structure includes B2B relationships with pricing plans based on the complexity and scope of the services rendered. While specific pricing details and flagship services are not disclosed, the company's offerings are designed to maximize the impact of research outcomes, ensuring that clients receive data-driven insights that accelerate their discovery processes.

In May 2025, Vugene raised EUR 1 million in venture funding led by Superhero Capital, with participation from NGL Ventures and Coinvest Capital. The company will utilize the funding to accelerate its growth as a global service provider that transforms complex biological data into actionable insights. Vugene aims to design and launch new products that enhance their multi-omics platform, with plans to expand into new markets including Asia and North America by the end of 2025.